HC Wainwright Comments on Insmed’s Q2 Earnings (NASDAQ:INSM)

Insmed, Inc. (NASDAQ:INSM) – Research analysts at HC Wainwright raised their Q2 2026 earnings estimates for Insmed in a research note issued to investors on Thursday, March 26th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings per share of ($1.00) for the quarter, up from their prior forecast of ($1.05). HC Wainwright has a “Buy” rating and a $245.00 price objective on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share. HC Wainwright also issued estimates for Insmed’s Q3 2026 earnings at ($0.84) EPS, Q4 2026 earnings at ($0.58) EPS, FY2027 earnings at $0.22 EPS, FY2028 earnings at $2.40 EPS, FY2029 earnings at $6.01 EPS and FY2030 earnings at $10.09 EPS.

INSM has been the topic of a number of other research reports. Cantor Fitzgerald boosted their target price on shares of Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Rothschild & Co Redburn set a $263.00 target price on Insmed in a report on Thursday, December 4th. Wells Fargo & Company cut their price objective on shares of Insmed from $208.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday, March 23rd. TD Cowen set a $241.00 price objective on shares of Insmed in a research note on Thursday, December 18th. Finally, Barclays began coverage on shares of Insmed in a report on Tuesday, January 27th. They set an “overweight” rating and a $231.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Insmed has an average rating of “Buy” and a consensus price target of $210.19.

Insmed Price Performance

INSM opened at $145.30 on Monday. Insmed has a 12 month low of $60.40 and a 12 month high of $212.75. The company has a market cap of $31.32 billion, a PE ratio of -22.67 and a beta of 1.13. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. The company has a 50 day moving average of $150.13 and a 200 day moving average of $166.24.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The business had revenue of $263.84 million during the quarter, compared to the consensus estimate of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business’s revenue for the quarter was up 152.6% on a year-over-year basis. During the same period last year, the firm earned ($1.32) EPS.

Insider Activity at Insmed

In other Insmed news, CFO Sara Bonstein sold 748 shares of Insmed stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $156.34, for a total transaction of $116,942.32. Following the completion of the sale, the chief financial officer directly owned 79,758 shares in the company, valued at $12,469,365.72. The trade was a 0.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Michael Alexander Smith sold 640 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $156.27, for a total transaction of $100,012.80. Following the completion of the transaction, the insider directly owned 56,397 shares of the company’s stock, valued at approximately $8,813,159.19. This represents a 1.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 189,651 shares of company stock valued at $31,533,654. Company insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INSM. Hsbc Holdings PLC increased its stake in Insmed by 8,052.6% in the fourth quarter. Hsbc Holdings PLC now owns 123,267 shares of the biopharmaceutical company’s stock valued at $21,493,000 after acquiring an additional 121,755 shares during the last quarter. Rockefeller Capital Management L.P. lifted its stake in Insmed by 88.2% during the fourth quarter. Rockefeller Capital Management L.P. now owns 16,775 shares of the biopharmaceutical company’s stock worth $2,920,000 after purchasing an additional 7,863 shares during the last quarter. Corient Private Wealth LLC boosted its holdings in shares of Insmed by 34.1% in the 4th quarter. Corient Private Wealth LLC now owns 20,865 shares of the biopharmaceutical company’s stock worth $3,631,000 after purchasing an additional 5,305 shares in the last quarter. Keenan LLC purchased a new position in shares of Insmed in the 4th quarter worth about $369,000. Finally, Reflection Asset Management bought a new position in shares of Insmed during the 4th quarter valued at about $30,000.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.